Kornimate/medical-research-clean huggingface dataset:
development of a 3d spacer mattress for pressure relieving in cardiac surgery and evaluation of its efficacy

Conditions: Pressure Ulcer; Cardiac Surgery

Summary: in this study, researchers developed a mattress made of 3d spacer fabric to relieve pressure during cardiovascular surgery. following the development process, an initial assessment of the mattress's effectiveness was carried out on healthy volunteers. the same people lay first on the developed product and then on the surgical mattress in the supine position. in both cases, the pressure between the person and the mattress was measured using a force-sensitive resistor (using interlink's frs-406 series sensors). thirty patients were included in the initial evaluation. a randomised controlled trial was then carried out with patients undergoing surgery (patients were divided into two groups; (a) mattress developed by the researchers and (b) standard operating theatre mattress). sixty patients were divided into two groups using block randomisation. in the block randomisation, patients below or above body mass index 27 were equally distributed between the groups. pressure levels were measured continuously during surgery using the same sensors.

in this study, the researchers developed a mattress made of 3d spacer fabric for pressure relief during cardiovascular surgery. following the development process, an initial assessment of the mattress's effectiveness was carried out on healthy volunteers. the same people lay first on the developed product and then on the surgical mattress in the supine position. in both cases, the pressure between the person and the mattress was measured using a force-sensitive resistor (using interlink's frs-406 series sensors). 30 patients were included in the initial evaluation. a randomised controlled trial was then carried out with patients who underwent surgery (patients were divided into two groups; (a) mattress developed by the researchers and (b) operating theatre mattress in common use). 60 patients were divided into two groups using block randomisation. in the block randomisation, patients below or above body mass index 27 were evenly distributed between the groups. pressure levels were continuously measured during surgery using the same sensors. data were analysed using ibm spss software v26.

Eligibility criteria:
inclusion criteria: * being 18 years or older * not having a pressure ulcer prior to surgery * agreeing to participate in the study exclusion criteria: - not agreeing to participate in the study.

Keywords: pressure ulcer operating room cardiac surgery
clinical evaluation of two different attachment system

Conditions: Dental Implant

Summary: edentulous patients commonly experience a deterioration in the quality of life; both in terms of oral and general health. studies demonstrated that conventional dentures do not adequately restore masticatory function nor quality of life. in contrast, implant-supported overdentures are considered the standard of care for edentulous patients as they offer a more stable prosthesis that ultimately results in improved oral function and patient satisfaction. precision attachments such as studs, magnets, telescopic crowns or a bars are commonly used for implant supported overdentures. implant overdentures supported by stud attachments gained popularity for the rehabilitation of edentulous patients as they are self-aligning, offer dual retention and compensate for divergence between implants up to angles of 40 degrees. however, it has been documented that the stud attachment system (locators) requires a high frequency of maintenance, particularly with regard to the replacement of the matrix. in order to overcome some of these limitations of existing attachment systems, a newer system was developed consisting of a matrix made of polyetheretherketone (peek) instead of a polymeric material. this system has an amorphous diamond like carbon-based abutment coating (adlc) and it was claimed to be more resistant to wear. clinically and in vitro, no comparative studies have been performed addressing wear and retention of the traditional stud attachment and the newer adlc attachment. thus, the aim of the present study is to clinically and in vitro evaluate the adlc and study attachment system.


Eligibility criteria:
inclusion criteria: * fully edentulous patients encountering problems (functional, aesthetics) with existing dentures in the upper and lower jaw or patients seeking for implant-supported prostheses * adequate bone in the anterior mandible for the placement of implants (regular diameter implant with a minimal length of 10mm) in the canine region * written informed consent * ability to understand the procedure and to answer a questionnaire. exclusion criteria: * impaired cognitive function and/or manual dexterity * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * unable to attend follow-up examinations * known or suspected non-compliance, drug or alcohol abuse * presence of any uncontrolled systematic disease that could compromise implant surgery and implant long-term performance * history of radiotherapy in the head and neck region * heavy smoker (\>10 cig. /day * any potential allergies or hypersensitivity to chemical ingredients of material used * bruxism * presence of bone metabolic disorders (e.g. osteoporosis) * pregnant or lactating women
cohort/ethics study of patients with severe alcoholic hepatitis undergoing early liver transplantation

Conditions: Liver Diseases, Alcoholic; Alcohol-Related Disorders; Transplant; Failure, Liver; Transplant; Complication, Rejection; Liver Diseases; Hepatitis, Alcoholic; Alcohol-Induced Disorders

Summary: the purpose of this study is to develop a clinical understanding of early liver transplantation (elt) for patients with severe alcoholic hepatitis (sah) and identify the public's opinion regarding this practice.

the research study is designed to improve the investigators' understanding of early liver transplantation for patients with severe alcoholic hepatitis. the goal of this research is twofold: 1. establish a knowledge base necessary for appropriate liver transplant candidate selection by quantifying post-elt mortality for sah and compare to outcomes to liver transplantation for other indications 2. develop an ethical framework for implementation of these transplants for sah based on the opinions of healthcare providers and the general public.

Eligibility criteria:
inclusion criteria for severe alcoholic hepatitis patients: * patients with severe alcoholic hepatitis (sah) listed for liver transplantation at johns hopkins hospital (jhh), have not been sober for at least 6 months at time of waitlisting, and are at least 18 years old. exclusion criteria for severe alcoholic hepatitis patients: * non-sah patients listed for liver transplantation at jhh and patients who have been sober for at least 6 months at the time of waitlisting. inclusion criteria for non-sah comparison group: * patients 18 years or older undergoing liver transplantation at jhh for alcoholic liver disease and were sober for at least 6 months prior to transplantation. exclusion criteria for non-sah comparison group: * patients who do not meet inclusion criteria.

Keywords: liver transplant alcoholic liver disease
sti571 prospective randomized trial: spirit

Conditions: Chronic Myeloid Leukemia

Summary: to test whether increasing the dose of imatinib or combining it with ifnalpha or ara-c increases the rate of molecular response (as measured by the decrease in bcr-abl transcripts after 12 months of treatment) in patients with previously untreated cml in chronic phase. to compare overall survival in a selected arm according to molecular response at 1 year from randomization with the reference arm.

imatinib at 400 mg daily has emerged as the preferred therapy for newly diagnosed cml patients who do not undergo allogeneic stem cell transplant. a phase iii randomized study, comparing imatinib at 400 mg per day to interferon plus cytarabine in newly diagnosed chronic phase cml patients enrolled 1106 patients from june 2000 to january 2001. 553 patients were randomized to each treatment. for comparative purposes, at 6 months, 75% of patients randomized to imatinib obtained a major cytogenetic response with 51% complete responses. despite these impressive results, only a minority of patients treated with imatinib in this study achieved a molecular remission. when analyzed by log reduction in bcr-abl transcript levels using quantitative rt-pcr, 39% of patients achieved a 3-log reduction in bcr-abl levels, but only 13% and 3% achieved a 4- and 5-log reduction, respectively.2 to improve upon these results, various groups have tried higher doses of imatinib, and combinations of imatinib with interferon alpha or cytarabine. each of these studies has used cytogenetic responses as the major endpoint. each of these therapies has increased toxicity as compared to 400 mg of imatinib alone and the rates of molecular remissions have not been reported. thus the purpose of this study is to first determine whether higher doses of imatinib or combining imatinib with interferon or ara-c would result in higher rates of molecular responses and if so, in better survival.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients with bcr-abl positive cml in chronic phase. * patients within 14 weeks of diagnosis and previously untreated for cml except for hydroxyurea and/or anagrelide. * no evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly * ecog performance score of 0-2 * acceptable hepatic, renal, and cardiac function * informed consent signed up exclusion criteria: * depressive syndrome not controlled * uncontrolled medical illnesses. * women with childbearing potential and male patients who are unwilling or unable to use an adequate method to avoid pregancy for the entire period of the study

Keywords: cml imatinib interferon cytarabine
clinical application of fibroblast activation protein pet/mri in liver fibrosis

Conditions: Liver Fibrosis; Positron Emission Tomography; Magnetic Resonance Imaging

Summary: positron emission tomography (pet) provides a valuable tool for the diagnosis and staging of liver fibrosis. activation of hepatic stellate cell (hsc) is a key link in the pathophysiological development of liver fibrosis. in human liver tissue, fibroblast activation protein (fap) was only expressed in active hscs and fibroblasts, but not in static hscs. therefore, fap has become an excellent target for diagnosis and treatment of liver fibrosis. recently, radionuclide-labeled fibroblast activation protein inhibitors (fapi) as a new novel positron tracer has shown to be effective to detect various cancers. in this prospective study, the investigators will use the most advanced imaging equipments, integrated pet/mr, and pet/ct with gallium-68 (68ga) -fapi to image patients with or suspected of liver fibrosis, the aim is to explore the value of 68ga-fapi hybrid pet/mr and pet/ct in liver fibrosis.

liver fibrosis is a key step in the development of various chronic liver diseases (viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, etc.) to cirrhosis and an important link that affects the prognosis of chronic liver disease. fibrosis is histologically reversible, and early liver fibrosis can still be reversed to restore liver tissue to normal. however, due to the lack of specific initial symptoms and accurate non-invasive diagnostic methods, the onset of liver fibrosis is insidious. most patients have developed liver cirrhosis and/or hepatocellular carcinoma when they are diagnosed, and some even require liver transplantation. if liver fibrosis can be diagnosed accurately and treated early, the prognosis of chronic liver disease can be improved. positron emission tomography (pet) provides a valuable tool for the diagnosis and staging of liver fibrosis. activation of hepatic stellate cell (hsc) is a key link in the pathophysiological development of liver fibrosis. in human liver tissue, fibroblast activation protein (fap) was only expressed in active hscs and fibroblasts, but not in static hscs. therefore, fap has become an excellent target for diagnosis and treatment of liver fibrosis. recently, radionuclide-labeled fibroblast activation protein inhibitors (fapi) as a new novel positron tracer has shown to be effective to detect various cancers. in this prospective study, the investigators will use the most advanced imaging equipments, integrated pet/mr, and pet/ct with gallium-68 (68ga) -fapi to image patients with or suspected of liver fibrosis, the aim is to explore the value of 68ga-fapi hybrid pet/mr and pet/ct in liver fibrosis.

Eligibility criteria:
inclusion criteria: * patients with suspected or diagnosed or treated liver fibrosis. * subjects are able to understand and sign the informed consent voluntarily, with good compliance. exclusion criteria: * acute systemic diseases and electrolyte disorders. * pregnant or lactating women. * patients refuse to sign the informed consent.
transcranial direct current stimulation to reduce chronic pelvic pain in endometriosis

Conditions: Endometriosis

Summary: in the study it will be tested whether transcranial direct current stimulation can reduce the perception of pelvic pain in patients with endometriosis. hypothesis: transcranial direct current stimulation can reduce the perception of pelvic pain in patients with patients with endometriosis.


Eligibility criteria:
inclusion criteria: endometriosis chronic pain (more than 3 months) pain (vas \> 3/10) exclusion criteria: - contraindication to transcranial direct current stimulation pregnancy sever internal or psychiatric condition
tracking treatment pathways in adult patients with hyperkalemia.

Conditions: Hyperkalemia

Summary: this study aims to increase the understanding of hyperkalemia (hk) management, treatment patterns, and the treatment decision-making process for the management of patients with hk over a period of up to 12 months. the generation of real-world evidence (rwe) to understand the treatment management decision rationale and to prospectively describe patient characteristics, treatment management patterns among patients with hk is of importance to improve adherence to guidelines and improve patient care. the primary objective: • describe hk management decisions, their rationale and treatment expectations. the secondary objective: • describe baseline characteristics and longitudinal clinical variables in patients with hk. the exploratory objective: • describe patient awareness and satisfaction with their hk treatment management across the study period.

this study is a multinational, observational, prospective, longitudinal, cohort study that will include primary and secondary data collection. secondary data, collected as per routine clinical practice will be extracted from electronic health records (ehr) and manually entered into the electronic case report form (ecrf). primary data will be collected directly from patients and health care providers (hcps). prospective data collection will be performed for a period of 12 months and will include data collection at baseline, that is, the date of enrollment, and at 3-, 6-, 9-, and 12-months following baseline. the data collection timepoints in this study is irrespective of when the patient's medical visits are scheduled. there are no study specific patient visits mandated by protocol and study may be fully virtual.

Eligibility criteria:
patients meeting all the following inclusion criteria will be eligible for inclusion into the study: 1. age ≥18 years on the date of signing informed consent 2. hk with serum potassium (k+) level(s) greater than 5.0 mmol/l, collected during standard of care, within 21 days prior to the date of enrollment\* 3. provision of signed and dated informed consent (\*enrollment in study is defined as the date of informed consent and confirmation of study eligibility, whichever occurs later). patients will be excluded from the study if they meet any of the following criteria: 1. concurrent participation in any trial that includes the use of k+ binders as an investigational medicinal product (imp) 2. patients with pseudohyperkalemia 3. a life expectancy of less than six months, based on physician judgement 4. acute causes of hk such as infections and/or trauma to be determined by the principal investigator 5. scheduled renal transplant 6. involvement in the planning and/or conduct of the study

Keywords: treatment pathways, hyperkalemia, high level of serum potassium. treatment rationale, treatment objective, treatment expectations, heart failure and chronic kidney disease.
effects of e-cigarette flavors on youth tcors 2.0

Conditions: Nicotine Use Disorder

Summary: this study is an examination of the influence of sweet and cooling flavors on the appeal and abuse potential of nicotine-containing e-cigarettes among susceptible youth.

researchers will examine the influence of sweet and cooling flavors on the appeal and abuse potential of nicotine-containing e-cigarettes among susceptible youth. participants will rate the flavor intensity, coolness, sweetness, and irritation experienced using validated rating scales. forty youth (18-20 years of age) who have experience with e-cigarettes and will participate in 1 laboratory session. they will receive 1 nicotine concentrations (36mg/ml nicotine salt) during the session; during the session they will be exposed, in random order, to sweet (watermelon) and sweet-cooling (watermelon-menthol) flavors combined with the assigned session nicotine concentration.

Eligibility criteria:
inclusion criteria: * ages 18-20 years * able to read and write * used e-cigs at least 10 times in lifetime * used e-cigs in past 30 days exclusion criteria: * current use of non-prescription substances besides nicotine, marijuana, alcohol * any significant current medical or psychiatric condition * known hypersensitivity to propylene glycol * pregnant or lactating females * uncontrolled asthma * nut/e-liquid flavorant allergy * current marijuana (tetrahydrocannabinol) vaping + e-cigarette or vaping use associated lung injury (evali) symptoms
antibiotyping and prevalence of virulent genotypes among helicobacter pylori and their impact on response to therapy

Conditions: H Pylori Infection

Summary: * detection of primary antimicrobial susceptibility and resistance of helicobacter pylori infection. * detection of resistance and virulence genes of helicobacter pylori infection. * assessment of h pylori carcinogenicity gene. * evaluation of outcome and efficacy of antibiotics regimen will be used in our research. * evaluation of effect of other factors as diet (fatty and spicy meal), drugs as nsaids use, antibiotics for any cause on response of h pylori to antibiotics regimen.

helicobacter pylori (h. pylori) infection is one of the most common infections in humans, affecting more than half of the world population. new infections are thought to occur as a consequence of direct human-to-human transmission or environmental contamination. the prevalence of the infection varies widely in rural developing areas (more than 80%) compared to urban developed ones (less than 40%), as a consequence of different socioeconomic and hygienic conditions . the vertical mode is infection spread from ascendant to descendent within the same family, while horizontal transmission involves contact with individuals outside the family or environmental contamination. most individuals are infected by helicobacter pylori during early childhood; in developing countries. successful eradication is important to prevent the development of antibiotic resistance, as well as to reduce the number of treatments and procedures. thus, national/ regional antibiotic resistance data could be used to guide treatment regimens for h pylori infection . several clinical factors associated with increased rates of antibiotic resistant h. pylori, including history of previous antibiotic exposure, increasing age, female gender, ethnicity/race, extent of alcohol use, and non-ulcer dyspepsia . the primary antibiotic resistance of h. pylori is increasing worldwide. the overall resistance rate was found to be 4.55% for amoxicillin; 27.22% for clarithromycin; 39.66% for metronidazole; and 22.48% for levofloxacin. therefore, drug susceptibility result of these antibiotics is necessary to select the appropriate drug for the successful eradication of the infection. helicobacter pylori exhibit specific geographic distributions that are related to clinical outcomes. despite the high infection rate of h. pylori throughout the world, the genetic epidemiology surveillance of h. pylori still needs to be improved.

Eligibility criteria:
inclusion criteria: - any patient is above 18 years old with symptomatic h pylori infection patients diagnosed by positive h pylori ag in stool (naïve treatment). exclusion criteria: * patients who aren't eligible to endoscopy. * patients are under 18 years old * patient's refusal * history of antibiotics or proton pump inhibitor use during last month.

Keywords: h pylori infection
registry for acute decompensated heart failure patients

Conditions: Heart Failure, Congestive; Heart Decompensation

Summary: the purpose of the adhere study is to develop a multi-center, observational, open-label registry of the management strategies of patients treated in the hospital for acute heart failure in the united states.

the objective is to compile a clinical database on the strategy for the medical management of patients hospitalized with acute heart failure (hf). through the use of the information collected from acute care hospitals across the united states the following information may be coming out of this study: 1) assist hospitals in evaluating and improving quality of care for patients with acute hf by tracking quality indicators and providing benchmark data reports; 2) describe the demographic and clinical characteristics of patients who are hospitalized with acute hf; 3) characterize the initial emergency department evaluation and subsequent inpatient management of patients hospitalized with acute hf; 4) identify patient characteristics and medical care practices associated with improved health outcomes in those hospitalized with acute hf; 5) characterize trends and changes over time in the management of acute hf; 6) offer surveillance of adherence to practice guidelines as these emerge for the inpatient management of acute hf. observational study - no investigational drug administered

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years at the time of admission to the hospital * received or is eligible to receive a principal hospital discharge diagnosis of hf * decompensated hf is present as determined clinically by the patient care team exclusion criteria: * hf is present as a co-morbid condition, but is not a principal focus of diagnosis or treatment during this hospitalization episode

Keywords: heart failure, congestive heart decompensation